New seven-year findings from CooperVision’s pivotal MiSight 1 day contact lens clinical trial demonstrate that myopia control gains were retained 12 months following treatment cessation. Mean axial elongation data indicated no evidence of rebound effect.1,2,†
The study is the world’s longest continuous running soft contact lens clinical trial for myopia control. CooperVision previously reported that MiSight 1 day showed sustained slowing of myopia progression across multiple years of treatment. This was observed in a cohort that wore MiSight 1 day for the study’s first six years, as well as the original control group who were switched into MiSight 1 day for three years.3
“Our unparalleled research clearly illustrates the tremendous potential of MiSight 1 day for children of different ages and with different levels of myopia, regardless of when they start treatment.3 With these results, eye care professionals should be even more confident in prescribing MiSight 1 day,” said Paul Chamberlain, the study’s principal investigator and CooperVision Director of Research Programs.
The latest data analysis goes even deeper to illustrate that MiSight 1 day offers a highlydesired proportional myopia control treatment effect. Abnormal axial length growth slowed by an average of approximately 50% with all tested ages (eight to 17 years).4 Because younger children’s myopia progresses faster than in older children,5 introducing MiSight 1 day at the earliest opportunity may offer the maximum cumulative benefit over time.4
In the study’s seventh year, participants were transitioned from MiSight 1 day to a single vision contact lens to evaluate if treatment gains would be retained. Myopic progression then occurred only at anticipated ‘age-normal’ levels – not at an accelerated ‘catch-up’ rate that would offset prior myopia control gains.1,2 This indicates no rebound effect.
“We saw these children grow into young adults during their seven years in the study. It is personally, as well as professionally, fulfilling to know that the benefits of treatment are retained. As MiSight 1 day becomes more widely available, and as myopia management becomes the standard of care, I hope other eye care professionals will experience that same joy,” said study investigator Nicola Logan, Professor of Optometry and Physiological Optics, Aston University.
References
- Chamberlain P, Arumugam B, et al. Myopia Progression on Cessation of Dual-Focus Contact Lens Wear: MiSight 1 day 7-Year Findings. Optom Vis Sci 2021;98:E-abstract 210049.
- Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with No Evidence of a Rebound Effect. Optom Vis Sci 2021;98:E-abstract 215130.
- Arumugam B, Chamberlain P, Bradley A et al. The Effects of Age on Myopia Progression with Dual-Focus and Single Vision Daily Disposable Contact Lenses. OptomVis Sci 2020;97(E-abstract):205340, AAO 2020 Poster.
- Arumugam et al. Modelling age effects of myopia progression for the MiSight 1 day clinical trial. ARVO 2021.
- Chua, Sharon & Sabanayagam, Charumathi & Cheung, Yin-Bun & Chia, Audrey & Valenzuela, Robert & Tan, Donald & Wong, T-Y & Cheng, Ching-yu & Saw, Seang-Mei. (2016). Age of onset of myopia predicts risk of high myopia in later childhood in myopic Singapore children. Ophthalmic and Physiological Optics. 36. 388-394. 10.1111/opo.12305.